Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 5
2013 5
2014 15
2015 29
2016 46
2017 54
2018 53
2019 84
2020 63
2021 83
2022 59
2023 54
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

497 results

Results by year

Filters applied: . Clear all
Page 1
Cobimetinib.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999907 Free Books & Documents. Review.
No information is available on the clinical use of cobimetinib during breastfeeding. Because cobimetinib is 90% bound to plasma proteins, the amount in milk is likely to be low. ...The manufacturer recommends that breastfeeding be discontinued during cobimetinib …
No information is available on the clinical use of cobimetinib during breastfeeding. Because cobimetinib is 90% bound to plasm …
Cobimetinib.
Signorelli J, Shah Gandhi A. Signorelli J, et al. Ann Pharmacother. 2017 Feb;51(2):146-153. doi: 10.1177/1060028016672037. Epub 2016 Oct 4. Ann Pharmacother. 2017. PMID: 27701080 Review.
STUDY SELECTION AND DATA EXTRACTION: The literature search was confined to human studies published in English. Trials of cobimetinib for melanoma were prioritized. DATA SYNTHESIS: Cobimetinib is a reversible inhibitor of MEK1 and MEK2. ...The role of cobimetinib …
STUDY SELECTION AND DATA EXTRACTION: The literature search was confined to human studies published in English. Trials of cobimetinib …
Cobimetinib.
[No authors listed] [No authors listed] 2017 Jun 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Jun 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643968 Free Books & Documents. Review.
Cobimetinib is a tyrosine kinase receptor inhibitor that is used in combination with vemurafenib as therapy for selected forms of advanced malignant melanoma. The combination of cobimetinib and vemurafenib is commonly associated with serum enzyme elevations during t …
Cobimetinib is a tyrosine kinase receptor inhibitor that is used in combination with vemurafenib as therapy for selected forms of adv …
Cobimetinib (GDC-0973, XL518).
Andrlová H, Zeiser R, Meiss F. Andrlová H, et al. Recent Results Cancer Res. 2018;211:177-186. doi: 10.1007/978-3-319-91442-8_12. Recent Results Cancer Res. 2018. PMID: 30069767 Review.
Several MEK inhibitors have been studied for metastatic cancer treatment in the recent past. After trametinib, cobimetinib is another potent, selective oral MEK1/2 inhibitor that was approved by European Medicine Agency (EMA) and Food and Drug Administration (FDA) in 2015 …
Several MEK inhibitors have been studied for metastatic cancer treatment in the recent past. After trametinib, cobimetinib is another …
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Larkin J, et al. N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29. N Engl J Med. 2014. PMID: 25265494 Free article. Clinical Trial.
This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. METHODS: We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanom …
This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. METHODS: …
Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.
Indini A, Tondini CA, Mandalà M. Indini A, et al. Future Oncol. 2019 Mar;15(9):967-977. doi: 10.2217/fon-2018-0659. Epub 2019 Jan 14. Future Oncol. 2019. PMID: 30638071 Review.
The toxicity profile of cobimetinib is manageable and treatment discontinuation due to adverse events is uncommon. Present efforts are addressed to overcome resistance and improve long-term outcomes: based on the evidence of the immunomodulatory properties of BRAFi and MEK …
The toxicity profile of cobimetinib is manageable and treatment discontinuation due to adverse events is uncommon. Present efforts ar …
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators. Eng C, et al. Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16. Lancet Oncol. 2019. PMID: 31003911 Clinical Trial.
This phase 3 study was designed to assess atezolizumab plus cobimetinib in metastatic colorectal cancer. Here, we report the comparison of atezolizumab plus cobimetinib or atezolizumab monotherapy versus regorafenib in the third-line setting. ...INTERPRETATION: IMbl …
This phase 3 study was designed to assess atezolizumab plus cobimetinib in metastatic colorectal cancer. Here, we report the comparis …
Cobimetinib for metastatic melanoma.
[No authors listed] [No authors listed] Aust Prescr. 2017 Feb;40(1):30-31. doi: 10.18773/austprescr.2016.095. Epub 2017 Feb 1. Aust Prescr. 2017. PMID: 28246434 Free PMC article. Review. No abstract available.
Cobimetinib: First Global Approval.
Garnock-Jones KP. Garnock-Jones KP. Drugs. 2015 Oct;75(15):1823-30. doi: 10.1007/s40265-015-0477-8. Drugs. 2015. PMID: 26452567 Review.
Genentech (a subsidiary of Roche) and Exelixis are developing cobimetinib, an orally available small molecule, for the treatment of various cancers, including malignant melanoma and breast cancer. Cobimetinib inhibits the MEK (mitogen-activated protein kinase) compo …
Genentech (a subsidiary of Roche) and Exelixis are developing cobimetinib, an orally available small molecule, for the treatment of v …
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
Schmitt AM, Dumas L, Larkin J. Schmitt AM, et al. Expert Rev Anticancer Ther. 2022 Jan;22(1):17-25. doi: 10.1080/14737140.2022.2017286. Epub 2022 Jan 2. Expert Rev Anticancer Ther. 2022. PMID: 34904502 Review.
The IMspire150 trial investigated the combination of atezolizumab, cobimetinib and vemurafenib versus cobimetinib and vemurafenib alone. ...The combination is compared with the current standard of care including BRAF/MEK inhibition and treatment with immune checkpoi …
The IMspire150 trial investigated the combination of atezolizumab, cobimetinib and vemurafenib versus cobimetinib and vemurafe …
497 results